168541-70-6

Usage

Molecular structure

The compound has a complex molecular structure, containing a naphthyridine ring and a carboxamide group.

Substituents

The compound is substituted with a trifluoromethylphenylmethyl group, a dimethyl group, and a 4-methylphenyl group.

Functional groups

The compound is highly functionalized, possessing a range of different chemical properties due to the presence of diverse functional groups.

Potential applications

Due to its complex structure, the compound may have a variety of potential applications in fields such as chemistry, pharmaceuticals, and materials science.

Chemical properties

The compound's chemical properties are influenced by the presence of its various functional groups, which can affect its reactivity, solubility, and other properties.

Stability

The stability of the compound may be influenced by factors such as its molecular structure, functional groups, and environmental conditions.

Synthesis

The synthesis of the compound may involve multiple steps and require specific reagents and conditions to achieve the desired product.

Characterization

The compound may be characterized using various analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and elemental analysis.

Purity

The purity of the compound may be important for its intended use, and may be assessed using techniques such as high-performance liquid chromatography (HPLC) or gas chromatography (GC).

Safety

As with any chemical compound, appropriate safety precautions should be taken when handling and using 1,7-Naphthyridine-6-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8-dihydro-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-, including the use of personal protective equipment and proper disposal of waste materials.

Upstream product

• 168541-25-1 N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-N, 1-dimethyl-2-oxo-4-(2-pyridyl)-3-quinolinecarboxamide 

Relevant academic research and scientific papers

Heterocyclic compounds, their production and use as tachykinin reactor antagonists

A novel compound represented by the formula: STR1 wherein Ring A and Ring B respectively stands for an optionally substituted homo- or hetero-cyclic ring, and at least one of them stands for an optionally substituted heterocyclic ring stand; Ring C stands for an optionally substituted benzene ring; R stands for a hydrogen atom or an optionally substituted hydrocarbon residue; one of X and Y stands for --NR1 -- (R1 stands for a hydrogen atom or an optionally substituted hydrocarbon residue) or --O--, and the other stands for--CO-- or --CS--, or one of them stands for --N= and the other stands for =CR2 -- (R2 stands for a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon residue, an optionally substituted amino group or an optionally substituted hydroxyl group); n denotes 1 or 2 or salts thereof which have an excellent tachykinin receptor antagonistic action and inhibitory action on plasma extravasation.

Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyridopyridine

A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity.Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead 1a.Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyridopyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists.Among the compounds synthesized, N--7,8-dihydro-N,7-dimethyl-8-oxo-5-(substituted phenyl)-6-pyridopyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of 125I>BH-SP binding in human IM-9-cells) of 0.21-0.34 nM and ED50 values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg.These compounds exhibited significantly potent activity upon oral adiministration with ED50 values of 0.068-0.17 mg/kg.Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.